Tandem Diabetes Care, Inc. - Common Stock (TNDM)

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of Tandem Mobi for use as the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear.1 A new Tandem Mobi tubeless cartridge and infusion set converts the current Tandem Mobi pump into a tubeless device that can help simplify diabetes management with less frequent site changes, while offering the life-changing benefits of Control-IQ+ advanced hybrid closed-loop technology. The Tandem Mobi insulin pump is now cleared for tubeless and tubed insulin infusion options, making it the only pump that offers users the flexibility to choose the wear option that best meets their needs.

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval of a license amendment for the t:slim X2™ insulin pump with Control-IQ+™ automated insulin delivery (AID) technology. This approval adds compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor and expands the t:slim X2 system’s indications for use to people with type 1 diabetes during pregnancy and to adults with type 2 diabetes in Canada. Compatibility with the Freestyle Libre 3 Plus Sensor and availability of these expanded indications are expected in the second quarter of 2027.

Tandem Diabetes Care (NASDAQ:TNDM) reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distributio

Sheridan steps down as CEO while Mobi Tubeless nears FDA clearance

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 13.8% year ...

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 13.8% year...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (“Tandem” or the “Company”), a global diabetes technology company, today announced the appointment of Jeannette Bankes as president and chief executive officer (“CEO”), and a member of its Board of Directors, effective November 16, 2026. Ms. Bankes will succeed John Sheridan, who will retire at the end of 2026 after more than a decade of service to Tandem, as part of a planned leadership transition.

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026.

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings this Thursday afternoon. Here’s what investors should know. Tandem ...

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

From Insulin Management To Cell Replacement: The Diabetes Revolution Is Accelerating   New York, NY – October 7, 2026 – Diabetes cell therapy is moving into a very different phase. For years, the idea of replacing damaged or lost insulin-producing cells sounded more like a long-term scientific goal than a practical treatment strategy. That is […]

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes,1 is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom.

What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S...

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...

Over the last six months, Tandem Diabetes’s shares have sunk to $22.45, producing a disappointing 13.7% loss - a stark contrast to the S&P 500’s 10.5% gain. ...

Tandem Diabetes Care (NASDAQ:TNDM) highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump. Speaking at Canaccord’

Pump shipments surged 10% as pharmacy adoption accelerated.

Tandem Diabetes met Wall Street’s revenue and profit expectations in Q2, but the market responded negatively, likely reflecting investor caution around the p...

What Happened? Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 18.2% in the afternoon session after the company reported seco...

Tandem Diabetes Care (NASDAQ:TNDM) reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery techn